Ferring Receives Positive Vote from US FDA Advisory Committee for RBX2660
The FDA’s Vaccines and Biologicals Advisory Committee (VRBPAC) approved RBX2660, an investigational live microbiota-based biotherapeutic agent being tested for its potential to lower recurrent C. difficile infection (CDI) after antibiotic treatment, according to Ferring Pharmaceuticals, which made the announcement today….